More Expensive Breast Cancer Tx Tied to Improved Survival

This article originally appeared here.
Share this content:
More Expensive Breast Cancer Tx Tied to Improved Survival
More Expensive Breast Cancer Tx Tied to Improved Survival

(HealthDay News) -- More expensive breast cancer treatments are linked to a greater chance of survival, new research suggests. The study was published in the April issue of Health Affairs.

"Our findings indicate that in some instances, newer and costlier approaches may be leading to improved outcomes in breast cancer patients," senior author Cary Gross, M.D., director of Yale University's Cancer Outcomes Public Policy and Effectiveness Research Center in New Haven, Conn., said in a university news release. "Now we need to tackle the harder questions about what we can afford to pay, and find out which treatments are effective for each patient."

In conducting the study, the researchers looked at the Medicare billing records of 9,708 women across the United States. The women were between 67 and 94 years old. They all had stage 2 or 3 breast cancer. The researchers looked for trends in the women's treatment costs and survival rates between 1994 and 1996, and compared them to trends from 2004 and 2006.

The researchers found that the costs for treating women with stage 3 breast cancer jumped from $18,100 to roughly $32,600. Meanwhile, the five-year survival rate for these women improved from 38.5 to 52 percent. Treatment for women with stage 2 breast cancer increased by more than 40 percent. The average cost for treatment was $12,300 in 1996 and $17,400 in 2006, according to the researchers. Five-year survival rates for these women also improved, though more modestly, from 68 to 72.5 percent. Gross said that the rising costs stemmed largely from big increases in the cost of chemotherapy and radiation therapy.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

Medicaid Expansion Ups Preemptive Listing for Kidney Transplant

Medicaid Expansion Ups Preemptive Listing for Kidney Transplant

From pre- to post-expansion period, 59 percent relative increase in Medicaid-covered preemptive listings

BCG Vaccine Tied to Reduced Hyperglycemia in Type 1 Diabetes

BCG Vaccine Tied to Reduced Hyperglycemia in Type ...

Systemic shift in glucose metabolism from oxidative phosphorylation to aerobic glycolysis

Many Physicians Not Prepared for End-of-Life Talks With Patients

Many Physicians Not Prepared for End-of-Life Talks With ...

Additional training, reimbursement may foster these critical conversations, authors say

is free, fast, and customized just for you!




Already a member?

Sign In Now »